Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone-guided interval extension of goserelin in prostate cancer
NL-OMON45500Completed
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Aug 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by Franciscus Gasthuis & Vlietland. Primary endpoint: Mean number of goserelin injections during follow-up. Started Aug 2017; status: completed.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON45500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45500.